newsfilter
← Latest News
GlobeNewswire·

AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial

  • AriBio announced topline results from the Phase 3 POLARIS-AD trial of oral AR1001 for early Alzheimer's disease at CTAD 2026 on November 16, 2026.
  • AR1001 met its primary efficacy endpoint in the prespecified Monotherapy population (n=604) with a -0.44 point treatment difference versus placebo on the CDR-SB at Week 52 (p=0.0266).
  • The primary endpoint result in the Monotherapy population represented a 31% slowing of clinical decline compared to placebo.
  • The study did not reach statistical significance in the Overall population (n=1,535), which showed a -0.11 point treatment difference (p=0.4015).
  • Secondary cognitive measures in the Monotherapy population favored AR1001, including a nominally significant improvement on the MMSE (0.7 points, p=0.0232) & a trend on ADAS-Cog 13 (-1.16 points, p=0.0798).
  • CSF biomarker analyses confirmed target engagement, showing significantly increased cGMP levels in both populations (p<0.0001 & p=0.0058) & a significant reduction in p-tau217 in the Monotherapy population (-5.34 pg/mL, p=0.0402).
  • AR1001 demonstrated a generally well-tolerated safety profile over the 52-week treatment phase, with treatment-emergent adverse events occurring in 69.0% of AR1001 recipients versus 66.4% of placebo recipients.
  • The most common non-serious adverse events associated with AR1001 included diarrhea, falls, & dizziness.
  • Fatal adverse events were reported in four participants (0.5%) receiving AR1001 & two participants (0.3%) receiving placebo.
  • The trial enrolled 1,535 participants across 13 countries, with 87.9% completing the 52-week double-blind period & 95.2% entering the ongoing open-label extension expected to conclude in Q3 2027.
  • AriBio plans to discuss the complete findings with the FDA to determine next steps for AR1001 development.
Company
AriBio Co., Ltd.
Keywords
AriBio Co., Ltd., AR1001, POLARIS-AD, Alzheimers Disease, Early AD, AD, AriBio, Phase 3 clinical trial, topline results, CTAD 2026, mirodenafil